EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
EKF Diagnostics announces that it has launched its next generation Hemo Control Point of Care (POC) diagnostics analyzer, providing laboratory accurate hemoglobin and hematocrit results in one simple test.
EKF Diagnostics, the global diagnostics company, announces that its PointMan™ DNA enrichment technology has been identified as an easy and useful method for non-invasively determining plasma EGFR T790M mutation status in late stage lung cancer patients.
PointMan™ shown to be a useful method for non-invasively determining plasma EGFR T790M mutation status in late stage lung cancer patients.
Sonia Nicholas, SelectScience's Clinical Editor spoke to Dr Ricardo Del Sol, Senior Lecturer at the College of Medicine, Institute of Life Science at Swansea University, UK, about using PointMan™ DNA enrichment kits and how working with EKF Diagnostics is leading to new advances in cancer diagnostics.
EKF Diagnostics announces that the Board of Directors have initiated a strategic review.
Audited final results for the year ended 31 December 2014.